UOC Ematologia ASST dei Sette Laghi
Welcome,         Profile    Billing    Logout  
 3 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Coscia, Marta
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/25
08/26
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated
2
5
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
05/24
05/24
CLL2323, NCT05694312: Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Recruiting
2
45
Europe
Ibrutinib 420 mg
Gruppo Italiano Malattie EMatologiche dell'Adulto
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Monoclonal B-Cell Lymphocytosis CLL-Type
05/25
11/26
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Recruiting
N/A
321
Europe
Venetoclax
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
01/23
10/25
ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -

Recruiting
N/A
190
Europe
acalabrutinib, Calquence
AstraZeneca, Yghea
Chronic Lymphocytic Leukemia
02/30
02/30
CLL2624, NCT06364033: Biological and Clinical Efficacy of Shingrix in Patients With CLL

Not yet recruiting
N/A
312
Europe
serologic response evaluation
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL-like MBL, Varicella-zoster Virus Reactivation
11/25
10/28
CLL2020, NCT04640909: Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients

Recruiting
N/A
23
Europe
Peripheral blood samples withdrawal
Gruppo Italiano Malattie EMatologiche dell'Adulto
CLL, Chronic Lymphocytic Leukemia
10/24
10/24
GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by

Recruiting
N/A
12500
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
10/26
10/26

Download Options